Masimo Corporation (MASI)
| Market Cap | 15.00B |
| Revenue (ttm) | 1.18B |
| Net Income (ttm) | 223.69M |
| Shares Out | 55.03M |
| EPS (ttm) | 3.86 |
| PE Ratio | 71.27 |
| Forward PE | 76.92 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $275.18 |
| Previous Close | $274.09 |
| Change ($) | 1.09 |
| Change (%) | 0.40% |
| Day's Open | 274.87 |
| Day's Range | 272.82 - 277.29 |
| Day's Volume | 98,490 |
| 52-Week Range | 203.81 - 284.86 |
Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.
Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 2.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the second quarter of 2021, ended July 3, 2021. Second Quarter 2021 Results: Product revenue increased 1....
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo announces the MX-7™ Technology Board, which supports all Masimo SET® and rainbow® parameters.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release second quarter 2021 financial results for the period ended July 3, 2021, after the market closes on Tuesday, July 27, 2021. The confer...
Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that the combination of two Masimo SedLine® parameters had high predictability for mortality 180 days after cardiac arrest.
The stock price of Masimo Corporation, a medical devices company best known for its remote patient monitoring systems, has seen a rise of 9.4% in last twenty-one trading days, while it is up 14% over th...
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
Masimo (NASDAQ: MASI) has announced that Radius Tº, a wearable, wireless thermometer, has received FDA 510(k) clearance for both prescription and over-the-counter (OTC) use on patients and consumers fiv...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Radius Tº™, a wearable, wireless continuous body temperature thermometer, has received FDA 510(k) clearance for prescription and OTC use.
Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that oxygen titration guided by Masimo ORi™ may reduce hospital stay and increase patient safety.
Masimo (MASI) reported earnings 30 days ago. What's next for the stock?
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 2:00 ...
Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.
New Study Assesses the Effects of Masimo Patient SafetyNet™ on Nursing Workflows in the General Ward
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A study evaluating Masimo Patient SafetyNet™ found that it reduced postoperative respiratory assessment nursing workload by more than 60%.
SNOQUALMIE, Wash.--(BUSINESS WIRE)--Spacelabs Healthcare and Masimo extend partnership to bring innovative patient monitors and advanced parameters to hospitals.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that Masimo O3® Regional Oximetry may aid in monitoring septic shock patients and may have value as a predictor of mortality.
Here are the stocks seeing the most insider buying this week
Brian Sullivan's weekly segment on Worldwide Exchange brings you the top five stocks seeing the most insider buying action this week.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announced the findings of the first study to evaluate the utility of PVi® on patients treated with nasal high-flow therapy.
Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.
Masimo (MASI) delivered earnings and revenue surprises of 2.27% and 0.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Masimo (NASDAQ:MASI) remain flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 7.22% year over year to $0.90, which beat the est...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the first quarter of 2021, ended April 3, 2021. First Quarter 2021 Results: Product revenue increased 10....
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) has changed the date for the release of its first quarter 2021 financial results to Monday, April 26, 2021 due to executive scheduling changes. The...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release first quarter 2021 financial results for the period ended April 3, 2021, after the market closes on Tuesday, April 27, 2021. The confe...
Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Radius PCG™, a portable mainstream capnograph that connects wirelessly to the Root® Patient Monitoring Hub, has received FDA clearance.
Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the 20th Annual Needham Healthcare Conference on Monday, April 12, 2021 at 3:45 ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study investigating the impact of rescue therapies on the brains of patients with severe COVID-19 used Masimo O3® Regional Oximetry.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study evaluated the accuracy of Masimo RRp® by comparing it to manual respiration rate counting on hospitalized, malnourished children.
Masimo (MASI) reported earnings 30 days ago. What's next for the stock?
The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new CCHD screening study with Masimo SET® pulse oximetry recommended the implementation of pulse oximetry screening for all newborns in Sri Lanka.
The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found the Masimo EMMA® Capnograph useful in the assessment of respiratory condition in children with tracheostomy.
According to the All-in-One Screener, a Premium feature of GuruFocus, four companies that have high profitability, business predictability and free cash flow growth are Autohome Inc. (NYSE:ATHM), Masimo...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo provides a variety of innovative monitoring solutions designed to improve maternal and newborn safety, including SET® pulse oximetry.
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
Masimo's (MASI) Rad-G with Temperature, which aids clinicians in seamless assessment of key vital signs through a single device, gets CE marking.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo Rad-G™ with Temperature, a rugged handheld device with SET® pulse oximetry, respiration rate, and temperature measurement, received CE marking.
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, M...
Shares of Masimo (NASDAQ:MASI) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 7.69% year over year to $0.98, which beat the estimate ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended January 2, 2021. Fourth Quarter 2020 Results: Total revenue for th...
About MASI
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion ind... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Aug 8, 2007 |
| CEO Joseph Kiani | Employees 2,000 |
| Stock Exchange NASDAQ | Ticker Symbol MASI |
Financial Performance
In 2020, Masimo's revenue was $1.14 billion, an increase of 21.96% compared to the previous year's $937.84 million. Earnings were $240.30 million, an increase of 22.47%.
Analyst Forecasts
According to 9 analysts, the average rating for Masimo stock is "Buy." The 12-month stock price forecast is 297.80, which is an increase of 8.22% from the latest price.